Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | RHOA | P61586 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15534718 | 0.86 | PKM (0.44) | GAASMN1; SMN2MEN1KMT2ARECQL | |
| SCHEMBL18327615 | 0.80 | JAK3 (0.36) | JAK3JAK1TYK2GAAJAK2 | |
| SCHEMBL18057641 | 0.67 | PDE9A (0.41) | JAK2KMT2AMCL1ALDH1A1 | |
| SCHEMBL15558289 | 0.67 | PARP1 (0.43) | MAPTSMN1; SMN2AKR1B1MEN1KMT2A | |
| SCHEMBL4885286 | 0.66 | BCAT2 (0.38) | MAPTGAASMN1; SMN2AKR1B1BCAT2 | |
| SCHEMBL1250605 | 0.63 | JAK1 (0.49) | JAK3JAK1TYK2MAPTGAA | |
| SCHEMBL10973261 | 0.63 | MAPT (0.44) | MAPTPTGDR2GAASMN1; SMN2AKR1B1 | |
| SCHEMBL18057654 | 0.63 | LMNA (0.43) | MAPTGAAMEN1KMT2ARECQL | |
| SCHEMBL3297721 | 0.61 | JAK2 (0.51) | JAK3JAK1TYK2JAK2RHOA | |
| SCHEMBL361662 | 0.60 | CXCL8 (0.67) | AKR1B1BCAT2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-15 | — | — | US | disclosed |
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-15 | — | — | US | disclosed |
| US-9434745-B2 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-09-06 | — | — | US | disclosed |
| US-9434745-B2 | 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362423-A1 | 7-OXO-THIAZOLOPYRIDINE CARBONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | CA7, TLR7, ALAD | JAK3 993/4885JAK1 864/4885TYK2 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.